Q2 2025 Recap: 7 Rheumatology Updates to Know

The second quarter of 2025 brought critical developments in rheumatology and autoimmune disease, as the FDA advanced several high-impact therapies and new data emerged to support innovative treatments. Regulatory milestones included the first-ever approval of inebilizumab for immunoglobulin G4-related disease, a landmark for this underserved patient population, and expanded indications for upadacitinib in giant cell arteritis, offering clinicians new tools for managing complex inflammatory conditions. Meanwhile, late-stage trial successes for TNX-102 SL in fibromyalgia and deucravacitinib in psoriatic arthritis hinted at promising future options for patients facing chronic pain and joint disease.